The Southern Medical Journal (SMJ) is the official, peer-reviewed journal of the Southern Medical Association. It has a multidisciplinary and inter-professional focus that covers a broad range of topics relevant to physicians and other healthcare specialists.

SMJ // Article

Original Article

Premalignant Colorectal Adenoma Detection in Individuals with Inherited CDH1 Genetic Mutations: A Single-Institution Experience

Authors: Adrienne B. Shannon, MD, Christine Laronga, MD, Caitlyn Balsay-Patel, MD, Laura V. Barton, MA, MS, LCGC, Luis Pena, MD, Marie C. Lee, MD, Julian A. Sanchez, MD, Jose M. Pimiento, MD, Seth I. Felder, MD, Andrew J. Sinnamon, MD, MS

Abstract

Objectives: Pathogenic germline CDH1 variants result in increased risk of gastric (GC) and invasive lobular (ILC) carcinomas with high penetrance. Limited data suggest a higher incidence of colorectal neoplasia in carriers of CDH1 mutations, but data remain limited on the risk of colorectal adenoma formation and the role of colonoscopy in this population.

Methods: Adult patients who underwent germline testing revealing a pathogenic mutation (PM) or variant of uncertain significance (VUS) in CDH1 were identified and seen in consultation were identified. Clinical and treatment characteristics were analyzed.

Results: Thirty-eight patients with CDH1 PM or VUS were identified at a single high-volume cancer center. Median age of CDH1 mutational analysis was 42 years (interquartile range 35–58). The majority of patients had deletion (N = 15, 39.5%) or nonsense (N = 6, 15.8%) mutations or VUS (N = 7, 18.4%). Twenty-six (68%), 20 (53%), and 11 (29%) had a family history of ILC, GC, and colon cancer, respectively. Eighteen (47%) patients underwent screening colonoscopy in addition to screening for GC and ILC; the median age at screening colonoscopy was 51.5 years (interquartile range 46–58) and 4 patients (22%) patients were younger than 45 years of age at the time of colonoscopy. Among patients younger than 45 years of age, the rate of adenoma detection was 50% (n = 2/4). Adenomas were identified in 8 (44.4%) patients, and of these patients, 6 (75%) had right-sided, 4 (50%) had left-sided, and 2 (25%) had both right- and left-sided adenomas. No patients were identified on colonoscopy to have colorectal cancers. When examining only patients with CDH1 PM (N = 31), 16 (51.6%) patients underwent screening colonoscopy, and 8 (50%) patients had adenomas detected. Conversely, of the two of the seven CDH1 VUS patients who underwent screening colonoscopy, neither patient had adenomas detected.

Conclusions: The association between inherited CDH1 variants and colorectal neoplasia remains undefined, but the rate of colorectal adenoma detection in this population of patients is significantly higher than that of the general population. Since these individuals already undergo upper endoscopy for their care, consideration of earlier colonoscopy and insurance approval may be warranted.
Posted in: Breast Cancer21

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Corso G, Montagna G, Figueiredo J, et al. Hereditary Gastric and Breast Cancer Syndromes Related to CDH1 Germline Mutation: A Multidisciplinary Clinical Review. Cancers (Basel) 2020;12:1598.
 
2. Blair VR, McLeod M, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol 2020;21:e386–e397.
 
3. Colvin H, Yamamoto K, Wada N, et al. Hereditary Gastric Cancer Syndromes. Surg Oncol Clin N Am 2015;24:765–777.
 
4. Corso G, Magnoni F, Massari G, et al. CDH1 germline mutations in healthy individuals from families with the hereditary diffuse gastric cancer syndrome. J Med Genet 2022;59:313–317.
 
5. Guilford P, Humar B, Blair V. Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer 2010;13:1–10.
 
6. Hansford S, Kaurah P, Li-Chang H, et al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol 2015;1:23–32.
 
7. Oliveira C, Pinheiro H, Figueiredo J, et al. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol 2015;16:e60–e70.
 
8. Pharoah PD, Guilford P, Caldas C. Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 2001;121:1348–1353.   
9. Ryan CE, Fasaye GA, Gallanis AF, et al. Germline CDH1 Variants and Lifetime Cancer Risk. JAMA 2024;332:722–729. doi:10.1001/jama.2024.10852.
 
10. Benusiglio PR, Malka D, Rouleau E, et al. CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. J Med Genet 2013;50:486–489.
 
11. National Comprehensive Cancer Network. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf. Published 2024. Accessed April 19, 2025.
 
12. National Comprehensive Cancer Network. NCCN Guidelines Version 1.2024, Genetic/ Familial High-Risk Assessment: Colorectal, Endometrial, and Gastric. https://www.nccn.org/professionals/physician_gls/pdf/genetics/ceg.pdf. Published 2024. Accessed April 19, 2025.
 
13. Richards FM, McKee SA, Rajpar MH, et al. Germline E-cadherin Gene (CDH1) Mutations Predispose to Familial Gastric Cancer and Colorectal Cancer. Hum Mol Genet 1999;8:607–610.
 
14. Lo W, Zhu B, Sabesan A, et al. Associations of CDH1 germline variant location and cancer phenotype in families with hereditary diffuse gastric cancer (HDGC). J Med Genet 2019;56: 370–379.
 
15. Hamilton LE, Jones K, Church N, Medlicott S. Synchronous appendiceal and intramucosal gastric signet ring cell carcinomas in an individual with CDH1-associated hereditary diffuse gastric carcinoma: a case report of a novel association and review of the literature. BMC Gastroenterol 2013;13:114.
 
16. Adib E, El Zarif T, Nassar AH, et al. CDH1 germline variants are enriched in patients with colorectal cancer, gastric cancer, and breast cancer. Br J Cancer 2022;126:797–803.
 
17. Passi M, Gamble LA, Samaranayake SG, et al. Association of CDH1 Germline Variants and Colon Polyp Phenotypes in Patients With Hereditary Diffuse Gastric Cancer. Gastro Hep Adv 2023;2:244–251.
 
18. Asif B, Sarvestani AL, Gamble LA, et al. Cancer surveillance as an alternative to prophylactic total gastrectomy in hereditary diffuse gastric cancer: a prospective cohort study. Lancet Oncol 2023;24:383–391.
 
19. van der Post R, Vogelaar IP, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet 2015; 52:361–374.
 
20. Gallanis AF, Gamble LA, Samaranayake SG, et al. Short and long-term outcomes of prophylactic total gastrectomy in 54 consecutive individuals with germline pathogenic mutations in the CDH1 gene. J Clin Oncol 2024;42:421–430.
 
21. Chen Y, Kingham K, Ford JM, et al. A Prospective Study of Total Gastrectomy for CDH1-Positive Hereditary Diffuse Gastric Cancer. Ann Surg Oncol 2011;18:2594–2598.
 
22. Curtin BF, Gamble LA, Schueler SA, et al. Enhanced endoscopic detection of occult gastric cancer in carriers of pathogenic CDH1 variants. J Gastroenterol 2021;56:139–146.
 
23. Forrester JD, Foster D, Ford JM, et al. Surgery for Hereditary Diffuse Gastric Cancer: Long-Term Outcomes. Cancers (Basel) 2022;14:728.
 
24. Lee CYC, Olivier A, Honing J, et al. Endoscopic surveillance with systematic random biopsy for the early diagnosis of hereditary diffuse gastric cancer: a prospective 16-year longitudinal cohort study. Lancet Oncol 2023;24:107–116.
 
25. Laszkowsky M, Tang L, Vos E, et al. Factors associated with detection of hereditary diffuse gastric cancer on endoscopy in individuals with germline CDH1 mutations. Gastrointest Endosc 2023;98:326–336.
 
26. Yadav S, Hu C, Nathanson KL, et al. Germline Pathogenic Variants in Cancer Predisposition Genes Among Women with Invasive Lobular Carcinoma of the Breast. J Clin Oncol 2021;39: 3918–3926.